Researchers have observed reduced TKS5 mRNA levels and higher mutation rates in some other cancer types (up to 8% in uterine endometrioid carcinoma and stomach adenocarcinoma) (Supplementary Figure S1). This evidence concerns the gene SH3PXD2A and endometrial endometrioid adenocarcinoma.